


Supplementary Material

The Needs of Psoriasis Patients and Benefits of Apremilast in French Clinical Practice: Results From the Observational REALIZE Study

Denis Jullien^{1,2}; Marie-Aleth Richard³; Bruno Halioua⁴; Christel Bessette⁵; Christian Derancourt⁶; Anne Boulloc⁷


¹Department of Dermatology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France, denis.jullien@chu-lyon.fr; ²Lyon-1 University, Lyon, France; INSERM U1111 – CIRI, Lyon, France, denis.jullien@chu-lyon.fr; ³Department of Dermatology, Assistance Publique-Hôpitaux de Marseille, France, mariealeth.richard@ap-hm.fr; ⁴Dermatologist, Paris, France, haliouab@yahoo.fr; ⁵ICON / PRA, Nanterre, France, cbessett@amgen.com; ⁶Dermatologist, Gap, France, cderancourt@gmail.com; ⁷Amgen, Boulogne-Billancourt, France, aboulloc@amgen.com

Supplementary Fig. 1. Percent change from baseline BSA and PASI



Error bars represent standard deviation.


Supplementary Fig. 2. PASI scores at baseline, 6 months, and 12 months



Based on persistent patients with PASI scores at the specified timepoint. Error bars represent standard deviation. PASI scores range from 0 to 72, with scores >10 considered severe.

PASI, Psoriasis Area And Severity Index.

Supplementary Fig. 3. sPGA at baseline^a, 6 months^b, and 12 months^b



^aBased on FAS.

^bBased on persistent patients from FAS with non-missing values.

FAS, Full Analysis Set.